Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03481348
Other study ID # PES-ALS
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date February 1, 2018
Est. completion date July 21, 2020

Study information

Verified date March 2021
Source University of Ulm
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

During the course of ALS most patients develop swallowing deficits. In this pilot study we investigate if dysphagia in ALS can be improved by Pharyngeal Electrical Stimulation (PES). PES is Communauté Européenne (CE-) certificated and has been approved for treatment of neurological, oropharyngeal dysphagia. During PES, electrical stimuli are applied at the pharynx via a nasogastral tube with the aim of triggering reorganization processes in damaged brain structures. There is evidence of a positive effect of PES in Stroke and Multiple Sclerosis patients.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date July 21, 2020
Est. primary completion date July 21, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - possible, probable or definite ALS according to the revised El Escorial criteria (Brooks et al. 2000) - age >18 years - able to understand all information and to give full consent according to good clinical practice (GCP) - moderate ot severe dysphagia, defined by a mean value (all consistencies) of 4 Exclusion Criteria: - concurrent participation in another interventional trial - tracheostomy - severe psychiatric disorder or clinically manifest dementia - pulmonal or cardial disorder which constitutes a risk when inserting the tube into the pharynx - permanent cardiac pacemaker or defibrillator

Study Design


Intervention

Device:
Pharyngeal Electrical Stimulation
Pharyngeal Electrical Stimulation is applied at the pharynx via a nasogastral tube for 10 minutes per day on 3 consecutive days.

Locations

Country Name City State
Germany University of Ulm Ulm

Sponsors (1)

Lead Sponsor Collaborator
University of Ulm

Country where clinical trial is conducted

Germany, 

References & Publications (1)

Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Penetration Aspiration Scale (PAS) Score Degree of Penetration and Aspiration evaluated by fiberendoscopic evaluation of swallowing (FEES) day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90
Secondary Swallowing-Quality of Life Score (SWAL-QOL) swallowing-specific quality of life questionnaire day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90
Secondary Schluckbeeinträchtigungs-Skala (SBS) Score Clinical scale to evaluate severity of dysphagia day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90
Secondary Functional Oral Intake Scale (FOIS) Score Clinical scale to evaluate the impairment of oral food intake day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90
Secondary Dysphagia Severity Rating Scale (DSRS) Score Clinical scale to evaluate severity of dysphagia day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90
Secondary Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALS-FRS-R) Clinical scale to evaluate the severity of symptoms in ALS day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90
Secondary Frequency of Adverse Events Frequency of Adverse Events day 0 (=before PES), day 4 (=after PES), day 7, day 21, day 90
See also
  Status Clinical Trial Phase
Terminated NCT04428775 - A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease Phase 2
Recruiting NCT04998305 - TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps Phase 1/Phase 2
Recruiting NCT05951556 - Telehealth Implementation of Brain-Computer Interface N/A
Terminated NCT04579666 - MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) Phase 2
Recruiting NCT04082832 - CuATSM Compared With Placebo for Treatment of ALS/MND Phase 2/Phase 3
Completed NCT01925196 - Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
Completed NCT02496767 - Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year Phase 3
Recruiting NCT04816227 - Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
Active, not recruiting NCT04494256 - A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation Phase 1/Phase 2
Completed NCT03706391 - Study of ALS Reversals 4: LifeTime Exposures
Recruiting NCT04882904 - Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part. N/A
Completed NCT04557410 - Open Label Study: Treatment of ALS Fatigue With PolyMVA Phase 1
Active, not recruiting NCT04948645 - A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis Phase 1
Not yet recruiting NCT04089696 - Validation of the "ExSpiron©" in Patients With ALS N/A
Not yet recruiting NCT05860244 - Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients Phase 2
Not yet recruiting NCT04220190 - RAPA-501 Therapy for ALS Phase 2/Phase 3
Not yet recruiting NCT06450691 - Modeling Amyotrophic Lateral Sclerosis With Fibroblasts N/A
Recruiting NCT02917681 - Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis Phase 1/Phase 2
Active, not recruiting NCT03067857 - Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease Phase 1/Phase 2
Recruiting NCT02874209 - Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis N/A